WO2017177837A1 - 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 - Google Patents
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 Download PDFInfo
- Publication number
- WO2017177837A1 WO2017177837A1 PCT/CN2017/078935 CN2017078935W WO2017177837A1 WO 2017177837 A1 WO2017177837 A1 WO 2017177837A1 CN 2017078935 W CN2017078935 W CN 2017078935W WO 2017177837 A1 WO2017177837 A1 WO 2017177837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrimidine
- methyl
- pyridin
- compound
- cyclopentyl
- Prior art date
Links
- IAAQUOVTPAMQCR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-2-one Chemical class C1=CC=C2NC(=O)N=CC2=N1 IAAQUOVTPAMQCR-UHFFFAOYSA-N 0.000 title abstract 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title description 8
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 claims abstract description 9
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 13
- -1 2-pentyl Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract description 10
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract description 10
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000007858 starting material Substances 0.000 description 57
- 239000007787 solid Substances 0.000 description 43
- 230000015572 biosynthetic process Effects 0.000 description 37
- 239000012467 final product Substances 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000001308 synthesis method Methods 0.000 description 20
- ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 2,4-dichloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1Cl ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 0.000 description 19
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- RMULRXHUNOVPEI-UHFFFAOYSA-N tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)N=C1 RMULRXHUNOVPEI-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 125000003003 spiro group Chemical group 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- MNJBMPQTXVZMFZ-UHFFFAOYSA-N 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine Chemical compound C1CN(CC)CCN1CC1=CC=C(N)N=C1 MNJBMPQTXVZMFZ-UHFFFAOYSA-N 0.000 description 8
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 8
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 102000016736 Cyclin Human genes 0.000 description 6
- 108050006400 Cyclin Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 description 5
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 5
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000010190 G1 phase Effects 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 3
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000022983 regulation of cell cycle Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- PQLHCTKAQZYUMI-UHFFFAOYSA-N 2,4-dichloro-5-methylsulfanylpyrimidine Chemical compound CSC1=CN=C(Cl)N=C1Cl PQLHCTKAQZYUMI-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- GXFIJNNOECYQOJ-UHFFFAOYSA-N [2-[1-(1-methylpyrazol-4-yl)indol-4-yl]oxy-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound CN1N=CC(=C1)N1C=CC2=C(C=CC=C12)OC1=NC(=CC(=C1)CN)C(F)(F)F GXFIJNNOECYQOJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WDQBOJNUKPWWJW-UHFFFAOYSA-N 1-bromocycloheptane-1-carboxylic acid Chemical compound BrC1(CCCCCC1)C(=O)O WDQBOJNUKPWWJW-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical class ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- HBZHNVUMFPGVHW-UHFFFAOYSA-N 2-chloro-1h-indole Chemical compound C1=CC=C2NC(Cl)=CC2=C1 HBZHNVUMFPGVHW-UHFFFAOYSA-N 0.000 description 1
- GELMWIVBBPAMIO-UHFFFAOYSA-N 2-methylbutan-2-amine Chemical compound CCC(C)(C)N GELMWIVBBPAMIO-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- CJYDQTAWSHWBIT-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxy-2-methylpropyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC(C)(C)O)C=CC=1 CJYDQTAWSHWBIT-UHFFFAOYSA-N 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 description 1
- LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- SONNQRNOTIAJDS-GFCCVEGCSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(2R)-2,3-dihydroxypropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC[C@H](CO)O)C=CC=1 SONNQRNOTIAJDS-GFCCVEGCSA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- ISXSUKUXUPLGTD-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(5-oxopyrrolidin-2-yl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2NC(CC2)=O)C=CC=1 ISXSUKUXUPLGTD-UHFFFAOYSA-N 0.000 description 1
- FJPUKTJEFOXMJX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[1-(hydroxymethyl)cyclopropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2(CC2)CO)C=CC=1 FJPUKTJEFOXMJX-UHFFFAOYSA-N 0.000 description 1
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 1
- FVQKGQNSCKJPIJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN2C(OCC2)=O)C=CC=1 FVQKGQNSCKJPIJ-UHFFFAOYSA-N 0.000 description 1
- ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 description 1
- AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- JOZZAIIGWFLONA-UHFFFAOYSA-N 3-methylbutan-2-amine Chemical compound CC(C)C(C)N JOZZAIIGWFLONA-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- SKTUEXOQGUXVBO-UHFFFAOYSA-N 5-(4-cycloheptylpiperazin-1-yl)pyridin-2-amine Chemical compound C1=NC(N)=CC=C1N1CCN(C2CCCCCC2)CC1 SKTUEXOQGUXVBO-UHFFFAOYSA-N 0.000 description 1
- RDAKYBCAEKCIJN-UHFFFAOYSA-N 5-(4-cyclohexylpiperazin-1-yl)pyridin-2-amine Chemical compound C1=NC(N)=CC=C1N1CCN(C2CCCCC2)CC1 RDAKYBCAEKCIJN-UHFFFAOYSA-N 0.000 description 1
- AZUAKXZWDQATEE-UHFFFAOYSA-N 5-(4-cyclopentylpiperazin-1-yl)pyridin-2-amine Chemical compound C1=NC(N)=CC=C1N1CCN(C2CCCC2)CC1 AZUAKXZWDQATEE-UHFFFAOYSA-N 0.000 description 1
- GAPKLZRRWLERHL-UHFFFAOYSA-N 5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-amine Chemical compound C1CN(C(C)C)CCN1C1=CC=C(N)N=C1 GAPKLZRRWLERHL-UHFFFAOYSA-N 0.000 description 1
- KZSOCAIRCZPXHG-UHFFFAOYSA-N 5-(piperazin-1-ylmethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC=C1CN1CCNCC1 KZSOCAIRCZPXHG-UHFFFAOYSA-N 0.000 description 1
- SASUDXLROUWZCC-UHFFFAOYSA-N 5-[(4-cyclopropylpiperazin-1-yl)methyl]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1CN1CCN(C2CC2)CC1 SASUDXLROUWZCC-UHFFFAOYSA-N 0.000 description 1
- MMQCTXWUZNJUTF-UHFFFAOYSA-N 5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-amine Chemical compound C1CN(C)CCN1CC1=CC=C(N)N=C1 MMQCTXWUZNJUTF-UHFFFAOYSA-N 0.000 description 1
- HNUCPIHXVQJOFE-UHFFFAOYSA-N 5-[(4-propylpiperazin-1-yl)methyl]pyridin-2-amine Chemical compound C1CN(CCC)CCN1CC1=CC=C(N)N=C1 HNUCPIHXVQJOFE-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- NRLQBVLOUUPAMI-UHFFFAOYSA-N 8-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2CCC3(CNC(O3)=O)CC2)C=CC=1 NRLQBVLOUUPAMI-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- CARBZIJGMIXACE-UHFFFAOYSA-N BrC(C(=O)OC)=C=O Chemical compound BrC(C(=O)OC)=C=O CARBZIJGMIXACE-UHFFFAOYSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- IDUHVFHRPFQFBO-UHFFFAOYSA-N C1(CCC1)N1CCN(CC1)C=1C=NC(=CC=1)N Chemical compound C1(CCC1)N1CCN(CC1)C=1C=NC(=CC=1)N IDUHVFHRPFQFBO-UHFFFAOYSA-N 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 1
- NURAVVJODHQOMA-UHFFFAOYSA-N ClC1N(C=C(C=N1)O)C(C)C Chemical compound ClC1N(C=C(C=N1)O)C(C)C NURAVVJODHQOMA-UHFFFAOYSA-N 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KKFGZKBFBZYLJH-UHFFFAOYSA-N N-ethyl-N-propan-2-ylpropan-2-amine hydrazine Chemical compound C(C)(C)N(CC)C(C)C.NN KKFGZKBFBZYLJH-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 description 1
- BYWBCSRCPLBDFU-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)N BYWBCSRCPLBDFU-CYBMUJFWSA-N 0.000 description 1
- LJHFUFVRZNYVMK-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)O LJHFUFVRZNYVMK-CYBMUJFWSA-N 0.000 description 1
- LJHFUFVRZNYVMK-ZDUSSCGKSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3S)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H](CC1)O LJHFUFVRZNYVMK-ZDUSSCGKSA-N 0.000 description 1
- JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 description 1
- KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- KOKFKKDTWBKYTQ-UHFFFAOYSA-N methyl 1-bromocyclobutane-1-carboxylate Chemical compound COC(=O)C1(Br)CCC1 KOKFKKDTWBKYTQ-UHFFFAOYSA-N 0.000 description 1
- RNWRVPVPLQMTAP-UHFFFAOYSA-N methyl 1-bromocyclohexane-1-carboxylate Chemical compound COC(=O)C1(Br)CCCCC1 RNWRVPVPLQMTAP-UHFFFAOYSA-N 0.000 description 1
- YGWINKVROAENAL-UHFFFAOYSA-N methyl 1-bromocyclopentane-1-carboxylate Chemical compound COC(=O)C1(Br)CCCC1 YGWINKVROAENAL-UHFFFAOYSA-N 0.000 description 1
- RESWQIUWQHUEAW-UHFFFAOYSA-N methyl 1-bromocyclopropane-1-carboxylate Chemical compound COC(=O)C1(Br)CC1 RESWQIUWQHUEAW-UHFFFAOYSA-N 0.000 description 1
- IOBCLXSGWMFVQJ-UHFFFAOYSA-N methyl 2-bromo-2,2-difluoroacetate Chemical compound COC(=O)C(F)(F)Br IOBCLXSGWMFVQJ-UHFFFAOYSA-N 0.000 description 1
- ARPGZMIRSBUKBU-UHFFFAOYSA-N methyl 2-bromo-2-cyanoacetate Chemical compound COC(=O)C(Br)C#N ARPGZMIRSBUKBU-UHFFFAOYSA-N 0.000 description 1
- FVRCRECNPNQSKL-UHFFFAOYSA-N methyl 2-bromo-2-cyclohexylacetate Chemical compound COC(=O)C(Br)C1CCCCC1 FVRCRECNPNQSKL-UHFFFAOYSA-N 0.000 description 1
- LELJHXRBCOPSRN-UHFFFAOYSA-N methyl 2-bromo-2-cyclopentylacetate Chemical compound COC(=O)C(Br)C1CCCC1 LELJHXRBCOPSRN-UHFFFAOYSA-N 0.000 description 1
- PNUIIPDSXRMQKT-UHFFFAOYSA-N methyl 2-bromo-2-cyclopropylacetate Chemical compound COC(=O)C(Br)C1CC1 PNUIIPDSXRMQKT-UHFFFAOYSA-N 0.000 description 1
- MRSREVPILUWLKS-UHFFFAOYSA-N methyl 2-bromo-2-methylbutanoate Chemical compound CCC(C)(Br)C(=O)OC MRSREVPILUWLKS-UHFFFAOYSA-N 0.000 description 1
- PQUSVJVVRXWKDG-UHFFFAOYSA-N methyl 2-bromo-2-methylpropanoate Chemical compound COC(=O)C(C)(C)Br PQUSVJVVRXWKDG-UHFFFAOYSA-N 0.000 description 1
- CKDTYRDFEIGXNO-UHFFFAOYSA-N methyl 2-bromo-3-methylbutanoate Chemical compound COC(=O)C(Br)C(C)C CKDTYRDFEIGXNO-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical compound NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the invention discloses a heteropyridine pyrimidinone derivative as a CDK inhibitor and its application
- the present invention relates to the field of pharmaceutical preparation technology, and in particular to a heteropyridine pyrimidinone derivative as a CDK inhibitor and use thereof.
- CDK Cyclin-dependent kinase
- cyclin is important factors in cell cycle regulation.
- CDK can form a heterodimer with cyclin, in which CD K is a catalytic subunit, cyclin is a regulatory subunit, forms various cyclin-CDK complexes, phosphorylates different substrates, and promotes different cell cycle phases. And transformation.
- CDK kinases that bind to G1 phase cyclins mainly include CDK2, CDK4 and CKD6.
- Cyclin D mainly binds to CDK4 and CKD6 and regulates the latter activity;
- cyclin E binds to CDK2 in G1/S phase, and exhibits CDK 2 kinase activity to promote cell entry into S phase.
- the G2/M phase is mainly regulated by CDK1 kinase.
- Cyclin A and CyclinB bind to CDK1.
- CDK1 phosphorylates the substrate protein.
- M-phase triggering factor activates the late-promoting factor APC, which is ubiquitously linked to Cyclin.
- CDK inhibitors have emerged as a new anti-tumor drug in the global pharmaceutical industry, with more than 20 CDK inhibitors entering clinical outbreaks. Although the preclinical pharmacodynamics of anti-tumor effects of CDK inhibitors are significant, most of the previous clinical trial results were unsatisfactory. The main problems include the lack of efficacy and toxicity in solid tumors. (Guha M. Nat Rev Drug Disl 1:892, 2012). However, in the analysis of severe toxic side effects, some CDK inhibitor drugs lacked selectivity for CDK subtypes, and thus produced large side effects.
- CDK4 and CDK6 are two closely related kinases that bind to Cyclin D during the tumor cell cycle. Bringing the G1 phase into the S phase is essential for the cell cycle progression of DNA replication cell division. In more than 90% of human tumors, changes in the G1-S phase transition control mechanism were observed through various genetic and biochemical adaptations.
- P16 and human retinoblastoma inhibitory protein are important swelling and pain inhibitory proteins that regulate the cell cycle. The P16 gene protein inhibits the feedback loop of CDK4, Cyclin Dl and Rb, and prevents the excessive proliferation of cells by regulating the protein activity of Rb to achieve tumor suppression.
- CDK4 and CDK6 have been shown that in human tumors (such as breast and myeloma), activation of CDK4 and CDK6 leads to cell cycle changes. Inhibition of CDK4 and CDK6 prevents the inactivation of the tumor suppressor protein Rb and interferes with tumor cell cycle progression (Choi YJ and Anders L, Oncogene 33: 1890-903, 2014).
- CDK4/6 plays a key role in the disorder of cell cycle control in various solid tumors and hematological tumors.
- multiple CDK4/6 inhibitors are currently in clinical stage (eg, Palb OC iclib, LY283 5219, and LEE011).
- Clinical evaluation of these drugs also includes metastatic breast cancer, ovarian cancer, liposarcoma, non-small cell lung cancer, liver cancer, glioblastoma, melanoma, multiple myeloma and lymphoma.
- CDK inhibitor compounds have been disclosed, a large number of drugs for the treatment of CDK-related disorders, particularly CDK4/6 inhibitors, are still required due to CDK-mediated pathology. drug.
- One of the objects of the present invention is to provide a novel heteropyridine pyrimidinone derivative or a pharmaceutically acceptable salt thereof
- the second object of the present invention is to provide the use of such a compound as a novel CDK4/6 inhibitor for the preparation of a medicament for preventing or treating a disease associated with CDK4/6, which is involved in the disorder of cycle control involving CDK4/6.
- the various diseases caused, especially the treatment of malignant tumors including but not limited to breast cancer, ovarian cancer, prostate cancer, colorectal cancer, pancreatic cancer, liver cancer, melanoma, gastric cancer and solid tumors.
- the present invention provides a heteropyridine pyrimidinone derivative represented by the following formula I: or a pharmaceutically acceptable salt thereof:
- [0012] represents hydrogen, C r C 3 alkyl group is, C 3 -C 7 cycloalkyl;
- 2 represents an alkyl group of 5 , a C 3 -C 7 cycloalkyl group, a 5-6 membered heteroaryl group, a phenyl group, a substituted phenyl group
- R 3 represent hydrogen, C r C 3 alkyl group, a cycloalkyl group, an acetyl group, a hormone, trifluoromethyl, cyano or CONR C 3 -C 7 the 5 R 6;
- R 3 , R 4 together with the carbon atom to which they are attached form a C 3 -C 7 aliphatic ring;
- R 5 , R 6 represent hydrogen, methyl respectively;
- X 0, S
- n 0 or 1.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, and at least one compound of the formula (I) as described herein and a pharmaceutically acceptable salt thereof, as a CDK4/6 inhibitor Applications.
- Ci-C 3 alkyl as used herein means methyl, ethyl, n-propyl or isopropyl;
- dC ⁇ alkyl means methyl, ethyl, n-propyl , isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-3-butyl, 1,1- Dimethyl-1-propyl, 2,2-dimethyl-1-propyl;
- the "alkoxy of dC 3 " is methoxy, ethoxy, n-propoxy, isopropoxy
- the "halogen” means F, Cl, Br, I;
- C 3 -C , alkyl means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl;
- Exemplary compounds of the invention include, but are not limited to, the following Table 1 compounds:
- Examples of pharmaceutically acceptable salts include inorganic salts and organic salts such as hydrochlorides, hydrobromides, sulfates, phosphates, citrates, tartrates, succinates, maleates, Fumar Acid salt, tonsil salt and
- [0027] 6 is reacted with an amine ( 17 ) to obtain the target product I.
- the present invention relates to the heteropyridine pyrimidinone derivatives which are CDK4/6 inhibitors which are useful for various clinical diseases such as cancer caused by disorders of cell cycle control in which CDK4/6 is involved.
- diseases include, but are not limited to, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, liver cancer, melanoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, lung cancer, gastric cancer, pancreatic cancer.
- the derivative of the present invention can be used for the treatment of related cancers and other diseases by oral administration, injection or the like during the treatment of the disease.
- composition comprises a therapeutically effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the carrier refers to a conventional carrier in the pharmaceutical field, such as: a diluent, an excipient such as water, etc.; a binder such as a cellulose derivative, gelatin, polyvinylpyrrolidone, etc.; a filler such as starch; Such as calcium carbonate, sodium bicarbonate; in addition, other adjuvants such as flavoring agents and sweeteners may also be added to the composition.
- a diluent such as water, etc.
- a binder such as a cellulose derivative, gelatin, polyvinylpyrrolidone, etc.
- a filler such as starch
- other adjuvants such as flavoring agents and sweeteners may also be added to the composition.
- For oral administration it can be prepared into a conventional solid preparation such as a tablet, a powder or a capsule, etc.; for injection, it can be prepared as an injection.
- composition of the present invention can be prepared by a conventional method in the medical field, wherein the active ingredient is contained in an amount of 0.1 ⁇ 3 ⁇ 4 to 99.5 ⁇ 3 ⁇ 4 (weight ratio).
- the dosage of the present invention may vary depending on the route of administration, the age of the patient, the body weight, the type and severity of the disease to be treated, and the like, and the daily dose is 0.005-30 mg/kg body weight (oral) or 0.005-30 mg/ Kg body weight (injection).
- the present invention provides a novel heteropyridine pyrimidinone derivative or a pharmaceutically acceptable salt thereof.
- a novel CDK4/6 inhibitor for the preparation of a medicament for preventing or treating a disease associated with CDK4/6, which is caused by a disorder of cycle control involving CDK4/6, particularly a malignant tumor Treatment, including but not limited to breast cancer, ovarian cancer, prostate cancer, colorectal cancer, pancreatic cancer, liver cancer, melanoma, gastric cancer, and solid tumors.
- Step 2 -N- isopropyl-2-chloro-5-methoxy-4-amino (0.78g, 3.88mmol) was added DCM (15 mL) was added dropwise BBr 3 (14.5g, 58.2mmol) under ice-cooling in DCM (15 mL) solution, after completion of dropwise addition, the mixture was stirred at room temperature for 10 h, and methanol (10 mL) was added dropwise to quench the reaction.
- Step 3 2-Chloro-N-isopropyl-5-hydroxypyrimidine-4-ammonia (0.54 g, 2.89 mmol), methyl 2-bromoisobutyrate (0.63 g, 3.46 mmol), K 2 C0 3
- Step 5 6,6-Dimethyl-8-isopropyl-2-(5-(4-carboxylic acid tert-butyl ester-1-piperazinyl)-pyridin-2-amino)-6H- Pyrimidine [5,4-b][l,4]oxazine-7(8H)-one (0.50 g, 2.0 mmol) was added to ethyl acetate (5 mL).
- the synthesis was carried out in the same manner as in Example 1.
- the starting material was 2-chloro-6,6-dimethyl-8-cyclopentyl-6H-pyrimidine[5,4-b][1,4]oxazine-7.
- (8H)-ketone synthesis method similar to Example 1, starting materials 2,4-dichloro-5-methoxypyrimidine and cyclopentylamine
- 4-(6-aminopyridin-3-yl)piperidin Tert-butyl ester of azine-1-carboxylate.
- the synthesis was carried out in the same manner as in Example 1.
- the starting material was 2-chloro-6,6-dimethyl-8-cyclopentyl-6H-pyrimidine[5,4-b][1,4]oxazine-7. (8H)-ketone and 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine.
- the final product is 6,6-dimethyl-8-cyclopentyl-2-(5-(4-ethyl-1-piperazinyl)methyl-pyridin-2-amino)-6H-pyrimidine [5, 4-b][l,4]oxazin-7(8H)-one hydrochloride (1-3), white solid.
- Example 1 The synthesis was carried out according to the method of Example 1.
- the starting material was 2'-chloro-8'-cyclopentyl-spiro[cyclopropane-1,6'-pyrimidine[5,4-b][1,4]oxazine.
- -7'(8 ⁇ )-ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and methyl 1-bromocyclopropanecarboxylate) and 1-(2) -pyridyl) and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- Example 1 The synthesis was carried out according to the method of Example 1.
- the starting material was 2'-chloro-8'-cyclopentyl-spiro[cyclobut-1,6'-pyrimidine[5,4-b][ 1,4]oxazine.
- -7'(8 ⁇ )-ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and methyl 1-bromocyclobutanecarboxylate) and 1-( 2-pyridyl) and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- Example 1 The synthesis was carried out according to the method of Example 1.
- the starting material was 2'-chloro-8'-cyclopentyl-spiro[cyclopenta-1,6'-pyrimidine[5,4-b][ 1,4]oxazine.
- -7'(8 ⁇ )-ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and methyl 1-bromocyclopentanecarboxylate) and 1-( 2-pyridyl) and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- Example 1 The synthesis was carried out according to the method of Example 1.
- the starting material was 2'-chloro-8'-cyclopentyl-spiro[cyclohex-1,6'-pyrimidine[5,4-b][ 1,4]oxazine.
- -7'(8 ⁇ )-ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and methyl 1-bromocyclohexanecarboxylate) and 1-( 2-pyridyl) and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2'-chloro-8'-cyclopentyl-spiro[cyclohept-1,6'-pyrimidine[5,4-b][ 1,4]oxazine]-7'(8 ⁇ )-one (synthesis method is similar to that in Example 1, the starting materials are 2,4-dichloro-5-methoxypyrimidine and 1-bromocycloheptanecarboxylic acid A Ester) and 1-(2-pyridyl) and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6-acetyl-8-cyclopentyl-6H-pyrimidine[5,4-b][1,4]oxazine-7 (8H).
- a ketone (synthesis method similar to that in Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and methyl 2-bromo-2-carbonylacetate) and 1-(2-pyridyl) and Tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate.
- the final product is 6-acetyl-8-cyclopentyl-2-(5-(1-piperazinyl)-pyridin-2-yl)-6H-pyrimidine [5,4-b][l,4] Pyrazin-7(8H)-one hydrochloride (1-9), pale yellow solid.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6-cyano-8-cyclopentyl-6H-pyrimidine [5,4-b][l,4]oxazin-7 (8H).
- a ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and methyl 2-bromo-2-cyanoacetate) and 1-(2-pyridyl) And tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate.
- the final product is 6-trifluoromethyl-8-cyclopentyl-2-(5-(1-piperazinyl)-pyridin-2-amino)-6H-pyrimidine [5,4-b][l,4 Oxazine-7(8H)-one hydrochloride (1-11), pale yellow solid. MS (m/z): 464 [M+H]+.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6,6-difluoro-8-cyclopentyl-6H-pyrimidine [5,4-b][l,4]oxazine-7 ( 8H)-ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and 2-bromo-2,2-difluoroacetic acid methyl ester) and 1-(2 -pyridyl) and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- Example 1 The synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6-cyclopropyl-8-cyclopentyl-6H-pyrimidine [5,4-b][ 1,4]oxazine-7 (8H).
- -ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and 2-bromo-2-cyclopropylacetic acid methyl ester) and 1-(2-pyridine And 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- Example 1 The synthesis was carried out as in Example 1.
- the starting material was 2-chloro-6-isopropyl-8-methyl-6H-pyrimidine [5,4-b][l,4]oxazin-7 (8H).
- - Ketone synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine, methylamine and methyl 2-bromoisovalerate) and 5-[(4-B Piperazin-1-yl)methyl]pyridin-2-amine.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6-methyl-6,8-diethyl-6H-pyrimidine[5,4-b][l,4]oxazine-7 ( 8H)-ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine, ethylamine and methyl 2-bromo-2-methylbutanoate) and 5 -[(4-Methylpiperazin-1-yl)methyl]pyridin-2-amine.
- the final product is 6-methyl-6,8-diethyl-2-(5-(4-methyl-1-piperazinyl)methyl-pyridin-2-yl)-6H-pyrimidine [5,4 -b][l,4] Oxazine-7(8H)-one (1-16), white solid.
- Example 1 The synthesis was carried out as in Example 1.
- the starting material was 2-chloro-6-cyclopentyl-8-sec-butyl-6H-pyrimidine [5,4-b][ 1,4]thiazine-7 (8H).
- -ketone synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methylthiopyrimidine, sec-butylamine and methyl 2-bromo-2-cyclopentylacetate) and 5 - [(Piperazine-1-yl)methyl]pyridin-2-amine.
- the final product is 6-cyclopentyl-8-sec-butyl-2-(5-(1-piperazinyl)methyl-pyridin-2-yl)-6H-pyrimidine [5,4-b][l, 4] Thiazin-7(8H)-one hydrochloride (1-17), white solid.
- Example 1 The synthesis was carried out as in Example 1.
- the starting material was 2-chloro-6-cyclohexyl-8-tert-amyl-6H-pyrimidine[5,4-b][1,4]oxazine-7 (8H).
- a ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine, tert-amylamine and methyl 2-bromo-2-cyclohexylacetate) and 5-[ (4-Cyclopropylpiperazine-1-yl)methyl]pyridin-2-amine.
- the synthesis was carried out in the same manner as in Example 1.
- the starting material was 2-chloro-6-cycloheptyl-8-(3-methyl-2-butyl)-6H-pyrimidine [5,4-b] [l, 4] thiazide-7(8H)-one (synthesis method is similar to that in Example 1, the starting materials are 2,4-dichloro-5-methylthiopyrimidine, 3-methyl-2-butylamine and 2 -Methyl bromo-2-cycloheptylacetate) and 5-[(4-propylpiperazin-1-yl)methyl]pyridin-2-amine.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2'-chloro-8'-cyclopentyl-spiro[cyclopropane-1,6'-pyrimidine[5,4-b][1,4]oxazine. -7'(8 ⁇ )-ketone and 1-(2-pyridyl) and 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6-acetyl-8-cyclopentyl-6H-pyrimidine[5,4-b][1,4]oxazine-7 (8H). a ketone and 1-(2-pyridyl) and 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine.
- the final product 6-acetyl-8-cyclopentyl-2-(5-(4-ethyl-1-piperazinyl)methyl-pyridin-2-amino)-6H-pyrimidine [5,4-b ][l, 4]oxazin-7(8H)-one (1-26), pale yellow solid.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6-cyano-8-cyclopentyl-6H-pyrimidine [5,4-b][l,4]oxazin-7 (8H). a ketone and 1-(2-pyridyl) and 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine.
- the final product 6-cyano-8-cyclopentyl-2-(5-(4-ethyl-1-piperazinyl)methyl-pyridin-2-amino)-6H-pyrimidine [5,4-b ][l,4]oxazin-7(8H)-one (1-27), pale yellow solid.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2'-chloro-8'-cyclopentyl-spiro[cyclobut-1,6'-pyrimidine[5,4-b][1,4]oxazine. -7'(8 ⁇ )-ketone and 1-(2-pyridyl) and 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine.
- the synthesis of the compound 1-31 was carried out in the same manner as in Example 1, and the starting material was 2-chloro-6,6-dimethyl-8-(2-pyrimidinyl)-6H-pyrimidine [5,4-b] ][l,4]oxazin-7(8H)-one and 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine.
- the final product 6,6-dimethyl-8-(2-pyrimidinyl)-2-(5-(4-ethyl-1-piperazinyl)methyl-pyridin-2-amino)-6H-pyrimidine [5,4-b][l,4]oxazin-7(8H)-one (1-31), white solid.
- the synthesis of the compound 1-32 was carried out in the same manner as in Example 1, and the starting material was 2-chloro-6,6-dimethyl-8-(2-furyl)-6H-pyrimidine [5,4-b] ] [l,4]oxazin-7(8H)-one and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- the final product 6,6-dimethyl-8-(2-furyl)-2-(5-(1-piperazinyl)-pyridin-2-yl)-6H-pyrimidine [5,4-b] [1,4]oxazine-7(8H)-one hydrochloride (1-32), pale yellow solid.
- the synthesis was carried out according to the method of Example 1.
- the starting material was 2-chloro-6-carboxamide-8-cyclopentyl-6H-pyrimidine [5,4-b][1,4]oxazine-7 (8H) a ketone and 1-(2-pyridyl) and 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester.
- the synthesis was carried out as in Example 1.
- the starting material was 2-chloro-6,6-dimethyl-8-phenyl-6H-pyrimidine [5,4-b][l,4]oxazine-7 ( 8H)-ketone (synthesis method similar to Example 1, starting materials are 2,4-dichloro-5-methoxypyrimidine and aniline) and 4-(6-aminopyridin-3-yl)piperazine-1 - tert-butyl carboxylate.
- the final product is 6,6-dimethyl-8-(3-pentyl)-2-(5-(4-ethyl-1-piperazinyl)methyl-pyridin-2-amino)-6H-pyrimidine [5,4-b][l,4]oxazin-7(8H)-one (1-38), pale yellow solid.
- CDK4 protein kinase activity was measured using a Caliper mobility shift assay (see J. Biomol. Screen, 2009, PP31).
- the test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl 2 , 2 mM DTT), and 5 L of 10 ⁇ 3 ⁇ 4 DMSO dissolved 5 was added to a 384-well plate.
- the compound-free control well was 5 ⁇ of 10% DMSO
- the no-inactive control well was 5 ⁇ L of kinase buffer.
- the CDK4 enzyme solution (GST-CDK4 (l-30 3end)) diluted 2.5 times with ⁇ was added, and then incubated at room temperature for 10 min, and then the substrate solution Peptide FAM-P8 diluted 2.5 times was added. 28. Incubate for 3 h at C and stop the reaction with 25 ⁇ stop solution, Caliper EZ Reader II
- Activity test Caliper mobility shift detection technique (Caliper mobility shift)
- the CDK6 protein kinase activity was determined (see J. Biomol. Screen, 2009, PP31).
- the test compound was dissolved in DMSO and diluted with a kinase buffer solution (20 mM HEPES-pH 7.5, 0.01% Triton X-100, 10 mM MgCl 2 , 2 mM DTT), and 5 L of 10 ⁇ 3 ⁇ 4 DMSO dissolved 5 was added to a 384-well plate.
- the compound-free control well was 5 ⁇ of 10% DMSO
- the no-inactive control well was 5 ⁇ L of kinase buffer.
- the CDK6 enzyme solution (GST-CDK6 (l-32 6end)) diluted 2.5 times with ⁇ was added, and then incubated at room temperature for 10 min, and then the substrate solution Peptide FAM-P8 diluted 2.5 times was added. 28. Incubate for 40 min at C and stop the reaction with 25 ⁇ stop solution, Caliper EZ Reader II
- A indicates IC 5 . ⁇ 500nM
- B means 500nM ⁇ IC 5 . ⁇ 100nM
- C means 100nM ⁇ IC > 20nM
- D means IC 5 . ⁇ 20nM.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019502134A JP6661049B2 (ja) | 2016-04-11 | 2017-03-31 | Cdk阻害剤としてのヘテロ環置換ピリジノピリミジノン誘導体およびその薬学的に許容される塩、並びに、医薬品組成物 |
EP17781813.5A EP3444254B1 (en) | 2016-04-11 | 2017-03-31 | Heterocyclic-substituted pyridinopyrimidinone derivative as cdk inhibitor and use thereof |
US16/155,867 US10351578B2 (en) | 2016-04-11 | 2018-10-09 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610220275.5 | 2016-04-11 | ||
CN201610220275.5A CN107286180B (zh) | 2016-04-11 | 2016-04-11 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/155,867 Continuation US10351578B2 (en) | 2016-04-11 | 2018-10-09 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017177837A1 true WO2017177837A1 (zh) | 2017-10-19 |
Family
ID=60042197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/078935 WO2017177837A1 (zh) | 2016-04-11 | 2017-03-31 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10351578B2 (zh) |
EP (1) | EP3444254B1 (zh) |
JP (1) | JP6661049B2 (zh) |
CN (1) | CN107286180B (zh) |
WO (1) | WO2017177837A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112334451A (zh) * | 2018-02-15 | 2021-02-05 | 诺维逊生物股份有限公司 | 作为激酶抑制剂的杂环化合物 |
WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
TWI810230B (zh) * | 2017-12-21 | 2023-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015066696A1 (en) * | 2013-11-04 | 2015-05-07 | Forum Pharmaceuticals Inc. | Fused morphlinopyrimidines and methods of use thereof |
CN105218561A (zh) * | 2014-06-25 | 2016-01-06 | 上海艾力斯医药科技有限公司 | 稠合嘧啶环衍生物、其制备方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200100016A (es) * | 2000-01-25 | 2001-10-19 | Pirido[2,3,-d]pirimidin-2,7-diaminas inhibidoras de cinasas. | |
DK1470124T3 (da) * | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
WO2010039997A2 (en) * | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
WO2015161288A1 (en) * | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
-
2016
- 2016-04-11 CN CN201610220275.5A patent/CN107286180B/zh active Active
-
2017
- 2017-03-31 EP EP17781813.5A patent/EP3444254B1/en active Active
- 2017-03-31 WO PCT/CN2017/078935 patent/WO2017177837A1/zh active Application Filing
- 2017-03-31 JP JP2019502134A patent/JP6661049B2/ja active Active
-
2018
- 2018-10-09 US US16/155,867 patent/US10351578B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015066696A1 (en) * | 2013-11-04 | 2015-05-07 | Forum Pharmaceuticals Inc. | Fused morphlinopyrimidines and methods of use thereof |
CN105218561A (zh) * | 2014-06-25 | 2016-01-06 | 上海艾力斯医药科技有限公司 | 稠合嘧啶环衍生物、其制备方法及应用 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI810230B (zh) * | 2017-12-21 | 2023-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物 |
CN112334451A (zh) * | 2018-02-15 | 2021-02-05 | 诺维逊生物股份有限公司 | 作为激酶抑制剂的杂环化合物 |
US11174252B2 (en) | 2018-02-15 | 2021-11-16 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
EP3752491A4 (en) * | 2018-02-15 | 2021-12-01 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS |
WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US20190071453A1 (en) | 2019-03-07 |
JP2019510822A (ja) | 2019-04-18 |
JP6661049B2 (ja) | 2020-03-11 |
EP3444254A1 (en) | 2019-02-20 |
CN107286180B (zh) | 2019-07-02 |
US10351578B2 (en) | 2019-07-16 |
EP3444254A4 (en) | 2019-04-24 |
EP3444254B1 (en) | 2020-05-13 |
CN107286180A (zh) | 2017-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Poratti et al. | Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib | |
AU2013366513B2 (en) | Novel benzimidazole derivatives as kinase inhibitors | |
EP3444246B1 (en) | 2,4-disubstituted pyrimidine derivative as cdk inhibitor and use thereof | |
EP2736514B1 (en) | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors | |
EP2598508B1 (en) | Isoxazolo-quinazolines as modulators of protein kinase activity | |
MX2007008373A (es) | Derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina y su uso en terapia. | |
TW201632530A (zh) | Erk抑制劑 | |
US10351578B2 (en) | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | |
WO2008112695A2 (en) | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment | |
AU2007227602A1 (en) | Heterocyclic organic compounds for the treatment of in particular melanoma | |
EP2417125B1 (en) | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors | |
JP2010529990A (ja) | タンパク質キナーゼ阻害剤およびそれを使用するための方法 | |
CA2551948A1 (en) | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors | |
AU2011268906A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
WO2024088110A1 (zh) | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 | |
WO2008140850A1 (en) | Solid forms of a raf kinase inhibitor | |
CA2553243C (en) | Pyrrolo pyrimidine derivatives useful for treating proliferative diseases | |
WO2021180008A1 (zh) | 含脲结构的三芳环化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2019502134 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017781813 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017781813 Country of ref document: EP Effective date: 20181112 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17781813 Country of ref document: EP Kind code of ref document: A1 |